Humacyte, Inc. received a notification from Nasdaq on July 31, 2026, that its common stock failed to maintain the minimum $1.00 bid price requirement for 30 consecutive business days ending July 30, 2026. The company has been granted an initial compliance period of 180 calendar days, expiring on January 27, 2027, during which it must restore the closing bid price to at least $1.00 for a minimum of 10 consecutive business days. This notice does not immediately affect the listing or trading of HUMA shares on the Nasdaq Global Select Market, nor does it impact business operations. The company intends to monitor its stock price and consider options to regain compliance but cannot assure success. Humacyte, Inc. operates in the biotechnology industry, specializing in the development of human hemoglobin-based oxygen carriers.
